All In Biotech

Free tool

FAERS Monitor: Daunorubicin Hydrochloride

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050731 or its brand name (Daunorubicin Hydrochloride, Daunorubicin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,648

Serious

1,634

99% of reports

Hospitalization

767

Death reported

398

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • febrile neutropenia205
  • myelosuppression187
  • bacterial infection158
  • secondary immunodeficiency130
  • pyrexia127
  • clostridium difficile colitis115
  • off label use109
  • pancytopenia95
  • fungal infection91
  • viral infection86
  • pneumonia80
  • product use in unapproved indication80
  • neutropenia73
  • cytomegalovirus viraemia70
  • bronchopulmonary aspergillosis69

Reports by year received

View as table
YearReports
20046
200511
20066
200710
20088
20098
20107
201123
201292
201332
201417
201526
201621
201736
201898
2019108
2020111
2021127
2022203
2023212
2024204
2025123
2026159

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,511 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
secondary immunodeficiencySignal1301530.61284.4176,102
cytomegalovirus viraemiaSignal70204.0161.913,723
clostridium difficile colitisSignal115140.0117.215,564
bronchopulmonary aspergillosisSignal69114.690.97,590
bacterial infectionSignal158109.093.916,674
myelosuppressionSignal18766.658.211,976
febrile neutropeniaSignal20539.634.87,667
fungal infectionSignal9134.928.62,963
viral infectionSignal8633.126.92,640
pancytopeniaSignal9521.717.91,860
neutropeniaSignal736.95.5361
pyrexiaSignal1274.74.0370
product use in unapproved indicationSignal804.13.3188
pneumoniaSignal803.22.5117
off label use1091.61.324

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.